CL2021002491A1 - Receptores de células t mage a4 - Google Patents
Receptores de células t mage a4Info
- Publication number
- CL2021002491A1 CL2021002491A1 CL2021002491A CL2021002491A CL2021002491A1 CL 2021002491 A1 CL2021002491 A1 CL 2021002491A1 CL 2021002491 A CL2021002491 A CL 2021002491A CL 2021002491 A CL2021002491 A CL 2021002491A CL 2021002491 A1 CL2021002491 A1 CL 2021002491A1
- Authority
- CL
- Chile
- Prior art keywords
- tcr
- mage
- cell receptors
- relates
- cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invención se refiere a un receptor de células T aislado (TCR) específico para MAGE-A4 y un polipéptido que comprende una porción funcional del TCR. También están implicados un complejo de TCR multivalente, un ácido nucleico que codifica un TCR, una célula que expresa el TCR y una composición farmacéutica que comprende el TCR. La invención también se refiere al TCR para su uso como medicamento, en particular al TCR para su uso en el tratamiento del cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19165387.2A EP3714941A1 (en) | 2019-03-27 | 2019-03-27 | Mage-a4 tcrs |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002491A1 true CL2021002491A1 (es) | 2022-06-10 |
Family
ID=66000958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002491A CL2021002491A1 (es) | 2019-03-27 | 2021-09-24 | Receptores de células t mage a4 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20230159612A1 (es) |
EP (2) | EP3714941A1 (es) |
JP (1) | JP2022527635A (es) |
KR (1) | KR20210150440A (es) |
CN (1) | CN114126716A (es) |
AU (1) | AU2020249598A1 (es) |
BR (1) | BR112021019066A2 (es) |
CA (1) | CA3134076A1 (es) |
CL (1) | CL2021002491A1 (es) |
CO (1) | CO2021012587A2 (es) |
EA (1) | EA202192327A1 (es) |
IL (1) | IL286569A (es) |
MX (1) | MX2021011613A (es) |
SG (1) | SG11202110171QA (es) |
WO (1) | WO2020193767A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3139011A1 (en) * | 2019-05-08 | 2020-11-12 | Medigene Immunotherapies Gmbh | Engineered t cells |
WO2021195503A1 (en) * | 2020-03-27 | 2021-09-30 | 2Seventy Bio, Inc. | T cell receptors |
CN111647069B (zh) * | 2020-06-17 | 2022-06-21 | 深圳豪石生物科技有限公司 | 一种改进的tcr及其应用 |
WO2022190009A1 (en) | 2021-03-09 | 2022-09-15 | Cdr-Life Ag | Mage-a4 peptide-mhc antigen binding proteins |
CN115975003B (zh) * | 2021-03-09 | 2024-01-26 | 科士华(南京)生物技术有限公司 | Tcr、多肽、表达载体、宿主细胞、药物组合物和tcr获得方法 |
EP4091627A1 (en) | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
WO2023288267A1 (en) | 2021-07-14 | 2023-01-19 | 2Seventy Bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术(广东)有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
WO2023196997A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
EP2006376A1 (en) | 2007-06-21 | 2008-12-24 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
HUE048014T2 (hu) * | 2012-09-14 | 2020-05-28 | Us Health | MHC Class II-korlátozott MAGE-A3-at felismerõ T-sejt receptorok |
JP7240176B2 (ja) * | 2016-04-08 | 2023-03-15 | アダプティミューン・リミテッド | T細胞受容体 |
DK3440105T3 (da) * | 2016-04-08 | 2022-06-13 | Immunocore Ltd | T-cellereceptorer |
CN111328288A (zh) * | 2017-08-18 | 2020-06-23 | 磨石肿瘤生物技术公司 | 靶向共同抗原的抗原结合蛋白 |
-
2019
- 2019-03-27 EP EP19165387.2A patent/EP3714941A1/en not_active Withdrawn
-
2020
- 2020-03-27 JP JP2021560302A patent/JP2022527635A/ja active Pending
- 2020-03-27 CA CA3134076A patent/CA3134076A1/en active Pending
- 2020-03-27 SG SG11202110171QA patent/SG11202110171QA/en unknown
- 2020-03-27 BR BR112021019066A patent/BR112021019066A2/pt unknown
- 2020-03-27 MX MX2021011613A patent/MX2021011613A/es unknown
- 2020-03-27 KR KR1020217035022A patent/KR20210150440A/ko active Search and Examination
- 2020-03-27 EA EA202192327A patent/EA202192327A1/ru unknown
- 2020-03-27 AU AU2020249598A patent/AU2020249598A1/en active Pending
- 2020-03-27 WO PCT/EP2020/058779 patent/WO2020193767A1/en unknown
- 2020-03-27 US US17/441,861 patent/US20230159612A1/en active Pending
- 2020-03-27 EP EP20719942.3A patent/EP3946621A1/en active Pending
- 2020-03-27 CN CN202080039452.4A patent/CN114126716A/zh active Pending
-
2021
- 2021-09-22 IL IL286569A patent/IL286569A/en unknown
- 2021-09-24 CO CONC2021/0012587A patent/CO2021012587A2/es unknown
- 2021-09-24 CL CL2021002491A patent/CL2021002491A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3134076A1 (en) | 2020-10-01 |
MX2021011613A (es) | 2021-12-15 |
AU2020249598A1 (en) | 2021-10-28 |
IL286569A (en) | 2021-12-01 |
JP2022527635A (ja) | 2022-06-02 |
CN114126716A (zh) | 2022-03-01 |
WO2020193767A1 (en) | 2020-10-01 |
US20230159612A1 (en) | 2023-05-25 |
CO2021012587A2 (es) | 2022-02-28 |
EA202192327A1 (ru) | 2022-01-19 |
BR112021019066A2 (pt) | 2021-11-30 |
EP3946621A1 (en) | 2022-02-09 |
EP3714941A1 (en) | 2020-09-30 |
SG11202110171QA (en) | 2021-10-28 |
KR20210150440A (ko) | 2021-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002491A1 (es) | Receptores de células t mage a4 | |
EA202092032A1 (ru) | Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения | |
AU2023200884B2 (en) | Human mesothelin chimeric antigen receptors and uses thereof | |
PH12021550307A1 (en) | T Cell Receptor Constructs And Uses Thereof | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
CO2020008972A2 (es) | Nanopartícula de lípido que contiene ácido nucleico y uso de la misma | |
CR20190095A (es) | Nuevos receptores de linfocitos t e inmonoterapia basada en el uso de los mismos | |
CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
CO2020014180A2 (es) | Derivados de gip y usos de estos | |
CL2012001539A1 (es) | Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo. | |
EP3656387A3 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
BR112016027805A2 (pt) | receptores de células t do anti-papilomavírus humano 16 e7 | |
CR20190431A (es) | Formatos mejorados de receptor de unión a antígeno | |
UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
AR092188A1 (es) | ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO | |
DOP2014000199A (es) | Anticuerpos frente a los ligandos del receptor b1 de bradicinina | |
CO2019011018A2 (es) | Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas | |
PE20160528A1 (es) | Anticuerpos | |
BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
AR116048A1 (es) | Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión | |
CO2019009035A2 (es) | Proteínas de unión al receptor de glucagón y métodos para usarlas | |
CO2020006443A2 (es) | Métodos y composiciones para la dosificación de células t con receptor de antígeno quimérico alogénicas | |
BR112016027133A8 (pt) | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso |